NCT05268016

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 132 (actual)
• Sponsor: Meiji Pharma USA Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	ME3183	ME3183 capsule
DRUG	Placebo	Placebo capsule

Timeline

• Start date: 2022-03-24
• Primary completion: 2023-05-31
• Completion: 2023-05-31
• First posted: 2022-03-07
• Last updated: 2024-06-27
• Results posted: 2024-06-27

Locations

27 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study